PUBLIC COMPANY
save$NBIXNEUROCRINE BIOSCIENCES INC
$NBIX165.31-1.25%San Diego, CA, USupdated 14h ago
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
community read0 votes
pipeline
6
marketed
2
phase 3
2
catalysts ytd
6
approvals ytd
1
recalls ytd
0
Pipeline(6)
pipeline depth6 products
1Preclinical2Phase 32Marketed1Unknown
Marketed
VALBENAZINE TOSYLATE
Chorea
Marketedcrinecerfont
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
Phase 3direclidine citrate
Schizophrenia
Phase 3hydrocortisone MR
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
PreclinicalNBIP-2118
Obesity
drugINGREZZA SPRINKLE
1 INDICATIONS AND USAGE INGREZZA and INGREZZA SPRINKLE ar…
Synaptic vesicular amine transporter
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase2Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
- phase2Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)
- phase3NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- phase2A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
- phase3Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
- phase2Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
- phase3Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- phase2Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
🐶 Hiring Signal
News
- Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia pushAddex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for tr…biospace · 4d ago
- With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buysAfter emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squi…biospace · 8d ago
- STAT+: Who will get the first psychedelic approved?The biotech Compass Pathways has been seen as one of the frontrunners in the race to get the first psychedelic drug approved. But it could be a tight race, with a non-profit…stat · 13d ago
- Neurocrine defends Prader-Willi drug after another patient deathNeurocrine Biosciences will conduct a new study for the rare disease drug Vykat to explore dosing and safety in patients with Prader-Willi syndrome who have complex health issues.biospace · 13d ago
- FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concernsAfter cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aa…biospace · 24d ago
- STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancerVerastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarc…stat · 1mo ago
- After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forwardA schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.stat · 1mo ago
- Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”stat · 1mo ago
- STAT+: FDA adcomm members’ ties to industry under scrutinyNew research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…stat · 1mo ago
- STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and morePatient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drugstat · 1mo ago
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that